GBS News and Press, GBS Inc.

GBS ( NASDAQ: GBS ) said Tuesday it acquired Intelligent Fingerprinting (IFP), expanding the GBS platform of rapid, non-invasive diagnostic testing technologies and its geographical reach. GBS also began the process of changing its corporate name. GBS issued ~3M shares...

The transaction further solidifies GBS’ leadership in non-invasive, real-time diagnostic testing with an expanded portfolio and geographical reach GBS’ global footprint includes operations in Australia, United Kingdom and the US NEW YORK, Oct. 04, 2022 (G...

GBS, Inc. (GBS) Q4 2022 Earnings Conference Call August 31, 2022, 04:30 PM ET Company Participants Steven Boyages - Chairman and Interim CEO Spiro Sakiris - CFO Conference Call Participants John Vandermosten - Zacks SCR Presentation Operator...

GBS press release ( NASDAQ: GBS ): FY GAAP EPS of -$0.57. Revenue of $0.44M (-77.8% Y/Y). As of June 30, 2022, the Company’s cash, cash equivalents and marketable securities totaled approximately $8.2 million, compared to approximately $12.6 million on June 30, ...

- Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquisition - - Completed collection and analysis in a study with coincidental sampling of oral fluid and blood to evaluate the ...

NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the four...

The trial is single center, prospective study collecting coincident samples of oral fluids and blood to evaluate the time-course of glucose NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic...

NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that the Company and the University of Newcastle in Aus...

NEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care (the “Company”), today announced that the Company has adjourne...

GBS (NASDAQ:GBS) is trading 10% higher before the bell after it announced on Thursday an exclusive agreement to acquire  UK-based drug screening firm Intelligent Fingerprinting (IFP). Under the agreement, GBS has the exclusive right until December 31, to evaluate and negotiate ...